The 2026 review finds limited support for topical spironolactone in adult female acne, including persistent cases. Oral spironolactone has robust support for moderate-to-severe adult female acne, while the topical form looks promising but rests on small, mixed studies.
Spironolactone is a hormone-blocking drug that lowers androgen effects on oil glands. The oral tablet is prescribed for acne. The topical version is the same drug applied to skin as a cream, gel, or solution.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 2026 review covered
- How limited is the topical evidence?
- How does oral spironolactone compare?
- What topical treatment involves in practice?
- What to discuss before trying it?
What the 2026 review covered
The review searched PubMed and Google Scholar on 1 Sept 2025. It compared oral versus topical spironolactone for adult female acne, including persistent disease. Dove Medical Press published the analysis on 26 Sept 2026 in Clinical, Cosmetic and Investigational Dermatology, described in the full narrative review.
The authors weighed trial size, design, and directness. They treated adult female acne as the main use case. Persistent acne means breakouts that continue past adolescence or resist standard care.
How limited is the topical evidence?
Topical results are encouraging but thin. A systematic review cited in the 2026 briefing pooled 5 trials with 195 patients. It found fewer papules, closed comedones, and total lesions than placebo, with 2% spironolactone outperforming clindamycin on comedones, papules, and pustules. A separate review in the Journal of Clinical and Aesthetic Dermatology found only six small randomized trials treating 193 patients.
Formulations differed: 5% cream, 5% gel, 2% solution, or 1% nanogel. Results conflicted, with no supporting pharmacokinetic data. Small samples and varied formulas limit comparison. No large trial defines the best strength, base, or schedule. Readers should view topical use as early-stage rather than settled care.
How does oral spironolactone compare?
Oral spironolactone has the stronger record for moderate-to-severe adult female acne. PubMed indexes the 2026 conclusion that oral treatment is well supported while topical evidence remains limited and partly indirect, noted in the PubMed record. The key oral trial is SAFA, a phase 3 double-blind study. It randomized 410 women with persistent acne to spironolactone or placebo.
Clearer skin emerged by week 12 and widened through week 24, reported in the BMJ trial report. That contrast matters for expectations. Oral therapy has a defined population and timeline. Topical therapy does not yet have matching proof.
What topical treatment involves in practice?
Topical spironolactone is available only as an extemporaneously compounded cream, gel, or solution. Compounded drugs are not FDA-approved, with unpredictable effects and no standardized efficacy testing. No FDA-reviewed studies establish topical safety or effectiveness for acne or its equivalence to oral treatment.
Compounded use therefore rests on individual prescriber judgment. Adults considering it need counseling on off-label status. Practical roles suggested in the 2026 briefing include possible mild-to-moderate care, adjunct use, post-oral maintenance, or use when systemic therapy is contraindicated. Those roles fit patients seeking local treatment or avoiding systemic drugs.
What to discuss before trying it?
Bring a clear history to the visit. Note prior retinoids, benzoyl peroxide, antibiotics, hormonal therapy, pregnancy plans, and potassium or kidney issues relevant to spironolactone decisions.
Set a review date rather than using it open-ended. Track lesion counts, photos, and irritation. Return sooner if acne worsens rapidly, scars develop, or severe pain or swelling appears.
- Ask whether persistent acne is mild, moderate, or severe
- Ask whether topical use would replace or add to current treatment
- Ask which compounded strength and base the prescriber uses, and why
- Ask how long to trial it, how success will be judged, and when to stop
- Ask about off-label status, cost, and follow-up
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Topical Clascoterone Evidence Revisited in 2026: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Mediterranean and Vegan Diet Claims in the 2026 Acne Review: A Source-Checked 2026 Briefing for Adults With Persistent Acne